Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Somatostatin (SST-14 and SST-28)
Also known as: SST-14, SST-28, SRIF
Fourteen amino acids, a disulfide bridge, and a half-life measured in seconds. Somatostatin (SST-14) is the body's master inhibitory hormone, produced in the hypothalamus, pancreas, and gut to suppress growth hormone, insulin, glucagon, and gastric acid simultaneously. Roger Guillemin's lab isolated it from sheep brains in 1973. The catch: it disappears from your bloodstream in under three minutes. That ultrashort duration forced pharmacologists to engineer octreotide, lanreotide, and pasireotide as longer-lasting clinical substitutes. Native somatostatin stays in the research lab and ICU, where continuous IV infusion is the only delivery method that works.
What Is Somatostatin (SST-14 and SST-28)?
A 120-patient double-blind RCT proved native somatostatin could stop variceal bleeding better than placebo (36% failure vs. 59%)[1]. Then octreotide made the finding nearly irrelevant. Somatostatin (somatotropin release-inhibiting factor, SRIF, CAS 38916-34-6) is a cyclic peptide hormone that exists as SST-14 (14 amino acids, Cys3-Cys14 disulfide bridge) and SST-28 (an N-terminally extended 28-amino-acid form).
The mechanism is broad-spectrum inhibition. Somatostatin binds all five G protein-coupled somatostatin receptor subtypes (SSTR1 through SSTR5) at roughly equal nanomolar affinity. That receptor coverage shuts down growth hormone release from the pituitary, insulin and glucagon secretion from pancreatic islets, gastric acid output, and splanchnic blood flow. No other single endogenous peptide hits that many secretory targets at once.
Endocrinologists and gastroenterologists used continuous IV infusions (250 to 500 mcg per hour) for acute esophageal variceal hemorrhage through the 1990s. In the European ABOVE trial [2], adding somatostatin to sclerotherapy cut treatment failures to 35 of 101, against 57 of 104 on placebo. A separate 70-patient trial [3] found somatostatin as effective as sclerotherapy, with fewer major complications. The peptide also appears in diagnostic provocative testing for insulinoma localization and GH axis studies. PubMed lists over 39,000 citations.
The practical limitation is straightforward: enzymatic degradation at the Trp8-Lys9 and Phe7-Trp8 bonds wipes out circulating somatostatin in 1 to 3 minutes after IV delivery. No subcutaneous or oral route produces meaningful plasma levels. The pharmaceutical industry responded with octreotide (1.8-hour half-life), lanreotide (depot lasting 4 weeks), and pasireotide (12-hour half-life). Those analogs carry FDA approvals; native somatostatin does not. It remains research-only in the United States.
How Somatostatin (SST-14 and SST-28) Works
Five receptor subtypes, one peptide, and an inhibitory signal that touches nearly every secretory organ in the body. SST-14 locks onto SSTR1 through SSTR5 with roughly equal nanomolar binding. SST-28 skews toward SSTR5 with about 10-fold selectivity. All five receptors couple to inhibitory G proteins (Gi/Go).
The downstream cascade starts with the Gi alpha subunit suppressing adenylyl cyclase. Intracellular cyclic AMP drops. Protein kinase A activity falls. In pituitary somatotrophs, that kills GH gene transcription and blocks exocytosis of stored hormone. In pancreatic beta cells and alpha cells, the same pathway suppresses insulin and glucagon release.
The beta-gamma subunit does separate work. It opens G protein-coupled inwardly rectifying potassium (GIRK) channels, hyperpolarizing the cell membrane. It also inhibits voltage-gated N-type and L-type calcium channels. Less calcium entry means fewer secretory granules fuse with the membrane. The antisecretory effect is therefore double-locked: reduced cAMP signaling plus electrical silencing of the cell.
SSTR2 and SSTR5 engage protein tyrosine phosphatases SHP-1 and SHP-2, which strip phosphate groups from growth factor receptors. This produces the antiproliferative effects that make somatostatin receptors valuable targets in neuroendocrine tumor therapy (Lutetium-177 DOTATATE, FDA-approved for NETs).
Degradation happens fast. Endopeptidases cleave the Trp8-Lys9 bond and the Phe7-Trp8 bond within the disulfide-constrained ring. Plasma half-life: 1 to 3 minutes. The synthetic analogs survive by incorporating D-amino acids and shrinking the ring structure to shield those cleavage sites.
Somatostatin (SST-14 and SST-28) Benefits
- Somatostatin benefits center on broad-spectrum neuroendocrine inhibition and acute clinical applications requiring continuous IV infusion.
- Acute variceal hemorrhage control via splanchnic blood flow reduction was confirmed in a 120-patient double-blind RCT (36% failure rate vs. 59% placebo)[1], with a second trial showing equivalent efficacy to sclerotherapy [3].
- Growth hormone suppression begins within seconds of IV bolus, making it the standard tool in diagnostic provocative testing for insulinoma and GH axis physiology studies.
- Simultaneous inhibition of insulin, glucagon, gastric acid, pepsin, gastrin, secretin, CCK, VIP, motilin, and GIP from a single peptide provides a research window into multi-organ hormonal crosstalk that no synthetic analog fully replicates.
- Receptor pharmacology research depends on SST-14's equal affinity for all five SSTR subtypes; the synthetic analogs preferentially target SSTR2 and SSTR5, leaving SSTR1, SSTR3, and SSTR4 biology harder to study without the native ligand.
- The antiproliferative signal through SHP-1 and SHP-2 phosphatase activation on SSTR2-expressing neuroendocrine tumors laid the pharmacological foundation for Lutetium-177 DOTATATE (Lutathera), now FDA-approved for NET treatment.
Somatostatin (SST-14 and SST-28): Science vs Community Consensus
Native somatostatin (SST-14/SST-28) has strong clinical evidence for IV use in acute variceal hemorrhage and diagnostic GH suppression.
Read the evidence (key study, limitations)
The 1-3 min half-life makes all self-administered or outpatient protocols pharmacologically impossible. Synthetic analogs (octreotide, lanreotide, pasireotide) have superseded native SST for all routine clinical applications. 2024-2026 research focus has shifted to SSTR subtype roles in Alzheimer's disease (neprilysin regulation) and PRRT in NETs.
Burroughs AK et al. PMID 1976563: double-blind RCT (n=120): failure to control variceal bleeding 36% SST vs 59% placebo. ABOVE (PMID 9388396, n=205): SST added to sclerotherapy, treatment failure 35 of 101 vs 57 of 104 on placebo (p = 0.004). PMID 7913907 (n=70): SST as effective as sclerotherapy, with fewer major complications.
All clinical evidence is for supervised IV infusion in hospital/ICU settings. No valid self-administration protocol exists. Analogs have superseded native SST in most applications. No 2024-2026 clinical trials using native somatostatin for new indications were identified.
No self-administration community exists for native somatostatin.
Read the reports
Zero self-injection protocols found on r/peptides or bodybuilding forums. The biohacker community discusses inhibiting endogenous somatostatin (to enhance GH pulses): the opposite of exogenous dosing.
No biohacker or self-administration community exists. All evidence comes from supervised IV clinical/research protocols. The 1-3 minute half-life eliminates any practical self-administration pathway: this peptide cannot be made to work outside a hospital IV setting.
Somatostatin (SST-14 and SST-28) Dosage Guide
| Level | Rate | Frequency |
|---|---|---|
| Beginner | 250 mcg | Continuous IV infusion (mcg/hour) |
| Moderate | 250 mcg | Continuous IV infusion (mcg/hour) |
| Aggressive | 500 mcg | Continuous IV infusion (mcg/hour) |
This peptide does not belong in anyone's home refrigerator. Native somatostatin requires continuous IV infusion through a hospital pump because the 1-3 minute half-life means a single subcutaneous injection produces no meaningful blood levels. There is no self-administration protocol that works.
For the reconstitution math in clinical settings: a standard 3 mg vial dissolved in 50 mL of 0.9% NaCl gives 60 mcg per mL. Running at 250 mcg per hour means 4.2 mL per hour on the IV pump. Running at 500 mcg per hour means 8.3 mL per hour. Research-grade 0.25 mg vials are dissolved per the supplier's data sheet for lab or animal work; that setup is not a dose for people.
The detail most people miss: rebound monitoring is just as important as infusion monitoring. Stopping the drip isn't the end of the clinical event. GH, insulin, and glucagon all spike above baseline for one to two hours after cessation. Have dextrose 50% drawn up before you turn off the pump. Store lyophilized powder at minus 20 degrees Celsius; reconstituted solution lasts 24 hours at 2-8 degrees Celsius maximum. Do not refreeze.
Cycling
Native somatostatin is not used in cycling protocols due to its ultrashort half-life. Research and diagnostic applications typically involve single-session continuous IV infusions lasting minutes to hours. For variceal hemorrhage, infusions of 250-500 mcg/hour are maintained for 2-5 days. There is no established cycling regimen. Patients requiring long-term somatostatin receptor suppression should use FDA-approved analogs (octreotide, lanreotide, or pasireotide) under medical supervision.
Cycling protocols are not applicable to native somatostatin. The 1-3 min half-life restricts all use to single-session IV infusions lasting minutes to days. No chronic or cyclical self-administration regimen exists or is clinically appropriate. Long-term somatostatin receptor suppression requires switching to approved analogs (octreotide LAR, lanreotide Autogel, pasireotide) with established long-term safety frameworks.
Or use the universal Peptide Calculator for any peptide.
Somatostatin (SST-14 and SST-28) Protocols by Goal
Expected: Control of acute esophageal variceal bleeding via reduction of splanchnic blood flow and portal pressure. PMID 1976563 demonstrated 36% failure rate vs 59% placebo; comparable efficacy to sclerotherapy with fewer complications (PMID 7913907).
Monitor: Continuous ECG; blood glucose q1-2h during infusion and q30min for 2h post-cessation; hemodynamic monitoring (BP, HR); watch for rebound hypoglycemia at infusion stop.
How to Use Somatostatin (SST-14 and SST-28)
- 1Step 1
Confirm the clinical indication (acute variceal hemorrhage, diagnostic GH suppression, or approved research protocol). Native somatostatin is not used outside supervised clinical or research settings.
- 2Step 2
Establish IV access with continuous hemodynamic monitoring: ECG, automated blood pressure cuff (every 15-30 minutes), and pulse oximetry. Draw up atropine for bradycardia backup.
- 3Step 3
Reconstitute the 3 mg lyophilized vial with 50 mL of 0.9% NaCl. This yields a concentration of 60 mcg per mL. Research-grade 0.25 mg vials are dissolved per the supplier's data sheet for lab or animal work, not for people.
- 4Step 4
For variceal hemorrhage: administer a 250 mcg IV bolus over 3 to 5 minutes. Follow immediately with continuous infusion at 250 mcg per hour (4.2 mL per hour at 60 mcg/mL concentration). Rate may increase to 500 mcg per hour (8.3 mL per hour) based on clinical response.
- 5Step 5
For diagnostic infusion: administer 1 to 5 mcg per kg IV bolus, followed by continuous infusion at 1 to 5 mcg per kg per minute. For a 70 kg adult, that translates to a 70 to 350 mcg bolus.
- 6Monitor blood glucose every 1-2 hours during infusion
Treat any reading below 70 mg/dL with IV dextrose immediately.
- 7At infusion cessation: do not leave the patient unmonitored
Continue glucose checks every 30 minutes for 2 hours. Watch for rebound hypoglycemia, GH overshoot, and gastric acid rebound.
- 8Step 8
Discard any unused reconstituted solution after 24 hours.
Alternative Routes
Reference route; 100% bioavailability; the only route capable of maintaining therapeutic plasma concentrations
Requires IV pump, hospital access, and continuous monitoring. Single bolus provides only ~3-5 min of activity before plasma levels decay to sub-therapeutic levels.
No established therapeutic dose; no meaningful sustained effect at any SC dose
Used in research PK studies only. Rapid degradation by tissue endopeptidases at injection site prevents sustained plasma levels. SST-28 is modestly more resistant than SST-14 but still impractical for SC therapy. All self-injection protocols are pharmacologically unfounded.
Somatostatin (SST-14 and SST-28) Stacking Protocols
Works With
Avoid
Somatostatin suppresses both insulin and glucagon simultaneously; blood glucose effects are unpredictable. Rebound hypoglycemia risk at infusion cessation (glucagon suppression lifts before insulin recovers). Requires intensive glucose monitoring if co-administered in clinical setting.
Do not combineAdditive bradycardia; continuous ECG monitoring required during co-administration. Concurrent use requires careful hemodynamic oversight in hospital setting.
Enhanced negative chronotropic effects from additive calcium channel inhibition; avoid combination without continuous ECG monitoring.
Theoretical additive arrhythmia risk from somatostatin's cardiac electrophysiological effects (SSTR2/5 on cardiac conduction). Avoid combination without ECG monitoring.
Direct pharmacological antagonism: somatostatin suppresses pituitary GH release and may blunt exogenous GH effects. Concurrent use is pharmacologically counterproductive.
Do not combineRedundant SSTR2/5 agonism; octreotide is a longer-acting analog covering the same receptor profile. Concurrent use provides no additive benefit and increases side effect burden.
Do not combineEstimated Cost
Pricing updated 2026-04-09
Somatostatin (SST-14 and SST-28) Side Effects
Rebound hypersecretion after stopping the IV drip is the safety concern that matters most. When a continuous somatostatin infusion ends, GH, insulin, glucagon, and gastric acid all overshoot their baseline levels within minutes. In diabetic patients, the risk is specific: glucagon suppression lifts before insulin secretion fully recovers, opening a window for dangerous hypoglycemia. Dextrose 50% should be available at bedside. Blood glucose monitoring needs to continue every 30 minutes for at least two hours after cessation.
Bradycardia during IV infusion is the second priority. Somatostatin activates SSTR2 and SSTR5 on cardiac tissue. Heart rate can drop below the threshold where intervention is needed (sustained HR below 50 bpm). Patients on beta-blockers or non-dihydropyridine calcium channel blockers face additive risk. Continuous ECG monitoring is standard protocol, and atropine should be drawn up before the infusion starts.
Gastrointestinal effects are common during infusion. Nausea, abdominal cramping, and diarrhea reflect the abrupt suppression of GI motility and enzyme secretion. These tend to be transient because the half-life is so short; stop the drip and symptoms resolve in minutes.
Hyperglycemia from insulin suppression occurs during active infusion. Blood glucose can spike, especially in patients with pre-existing insulin resistance. Monitoring every one to two hours during infusion is the minimum standard.
Hypotension results from reduced splanchnic blood flow. That same vascular effect is therapeutically useful in variceal bleeding, but it creates problems in patients who are already hemodynamically unstable. Fluid resuscitation and vasopressor access are required for actively bleeding patients.
Prolonged continuous infusion (days, as in variceal hemorrhage protocols) carries the same chronic risks seen with somatostatin analogs: gallbladder stasis leading to sludge formation, fat malabsorption (steatorrhea), and potential vitamin B12 deficiency.
IV site pain and flushing are common with extended infusions but resolve quickly after the line is removed.
Pregnancy and breastfeeding: insufficient safety data exists. Avoid unless the clinical situation is life-threatening and no analog alternative is available. All use requires direct medical supervision in a facility equipped for hemodynamic and glucose monitoring.
When to get emergency help: sustained heart rate below 50 bpm, symptomatic hypoglycemia that doesn't respond to dextrose, signs of anaphylaxis, or hemodynamic collapse. When to stop the infusion: confirmed arrhythmia, refractory hypotension, or allergic reaction.
Common Issues & Solutions
Rebound hypersecretion post-infusion: GH, insulin, and glucagon overshoot baseline for 1-2 hours after cessation: have dextrose 50% available; monitor glucose aggressively in diabetic patients.
Bradycardia during infusion: Reduce rate or pause infusion; do not use in patients on beta-blockers or CCBs without continuous ECG monitoring; atropine should be available.
Blood glucose instability: Hyperglycemia (insulin suppression) during infusion and hypoglycemia (rebound) after cessation are both possible; monitor q1-2h throughout and for 2h post-stop.
No therapeutic effect with SC injection: Subcutaneous administration does not produce meaningful sustained effects: the 1-3 min half-life prevents accumulation; IV infusion is required for any pharmacological activity.
Post-infusion hypotension: Splanchnic vascular tone rebounds after cessation; ensure adequate fluid resuscitation; have vasopressors available in hemodynamically unstable patients.
Ask AI about this page
Ask AI for a second opinion on Somatostatin (SST-14 and SST-28) dosing and side effects
Contraindications
- Known hypersensitivity to somatostatin or any formulation component
- Severe cardiac conduction disorders (risk of bradycardia and arrhythmia)
- Type 1 diabetes with brittle glycemic control (risk of severe hypoglycemia upon withdrawal)
- Pregnancy and breastfeeding (insufficient safety data; avoid unless clearly necessary)
- Severe hepatic impairment (altered metabolism and unpredictable clearance)
- Pre-existing hypotension or hemodynamic instability (risk of further blood pressure reduction)
- Concurrent use of drugs with strong bradycardic effects without cardiac monitoring
Drug Interactions
- Insulin and oral hypoglycemics: Somatostatin suppresses both insulin and glucagon; blood glucose may become unpredictable; intensive monitoring required
- Beta-blockers: Additive bradycardia risk; continuous cardiac monitoring recommended during co-administration
- Calcium channel blockers (verapamil, diltiazem): Enhanced negative chronotropic effects; avoid combination without ECG monitoring
- Growth hormone therapy: Somatostatin directly antagonizes exogenous GH effects; concurrent use is pharmacologically counterproductive
- Cyclosporine: May reduce cyclosporine absorption and blood levels (documented with octreotide; likely applies to native somatostatin)
- QT-prolonging medications: Theoretical additive risk of cardiac arrhythmias given somatostatin's cardiac effects
- Redundant SSTR2/5 agonism; octreotide is a longer-acting analog covering the same receptor profile. Concurrent use provides no additive benefit and increases side effect burden.
Product Quality
No compounding market exists for native somatostatin in the US (not on FDA 503A/503B approved bulk lists). Research-grade somatostatin is sold only as a lab reagent. Any self-administration attempt bypasses the continuous monitoring required for safe clinical use.
- Legitimate clinical use requires pharmaceutical-grade IV preparations (e.g., Stilamin 3 mg: registered in select European markets, not FDA-approved in US).
- Research-grade purity should be verified by HPLC certificate (>99%) and mass spec for identity confirmation; somatostatin analogs may be misrepresented as native SST.
- No FDA 503A/503B-compliant compounded somatostatin products are available in the US.
- All clinical use requires hospital or research facility with IV access, glucose monitoring, and cardiac monitoring capabilities.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Blood glucose | Every 1-2 hours during infusion; at cessation; every 30 min for 2 hours post-cessation | 80-180 mg/dL; treat hypoglycemia (<70 mg/dL) aggressively with IV dextrose |
| Heart rate / continuous ECG | Continuous monitoring during entire infusion period | HR >50 bpm; pause infusion if sustained bradycardia or conduction changes |
| Blood pressure | Every 15-30 minutes during infusion | SBP >90 mmHg; SBP >100 mmHg preferred in high-risk patients |
| Serum GH (research/diagnostic use only) | Baseline; during infusion peak; 30-60 min and 90-120 min post-cessation | Not listed |
Insulin suppression causes hyperglycemia during infusion; rebound hypoglycemia risk when glucagon suppression lifts before insulin recovers at infusion stop
Bradycardia risk via cardiac SSTR2/5; additive effect with beta-blockers, CCBs, and any bradycardic agents
Splanchnic vasodilation reduction can cause hypotension; risk elevated in actively bleeding patients with pre-existing hemodynamic compromise
Confirms GH suppression efficacy for diagnostic purposes; documents rebound hypersecretion kinetics
Somatostatin (SST-14 and SST-28) Before and After
Rapid onset of GH suppression and reduction of splanchnic blood flow. Peak plasma concentration achieved almost immediately with IV administration.
Plasma levels decline rapidly (half-life ~1-3 min). GH, insulin, and glucagon secretion are acutely suppressed. Gastric acid output decreases measurably.
Sustained suppression of GH, insulin, glucagon, and GI hormones for the duration of infusion. Steady-state plasma levels achieved within 10-15 minutes. Portal pressure reduction evident in variceal bleeding applications.
Rapid clearance from plasma. Rebound hypersecretion of GH and other hormones may occur within minutes of cessation. Blood glucose may fluctuate: monitor for rebound hypoglycemia or hyperglycemia.
All direct hormonal effects fully reversed. No residual activity expected beyond 15-30 minutes. Rebound GH elevation typically normalizes within 1-2 hours.
What to Expect
Seconds to 1 minute (IV bolus): The peptide reaches peak plasma concentration almost instantly. GH suppression kicks in. Splanchnic blood flow starts dropping. Insulin and glucagon output falls within the first minute. Transient flushing and brief hypotension can occur at this stage.
1-15 minutes (bolus only, no infusion): Without a continuous drip, plasma levels halve every 1-3 minutes. All hormonal suppression reverses within 15 to 20 minutes of a single bolus. This window confirms why a bolus alone has no therapeutic staying power.
During continuous infusion (minutes to hours): Steady-state plasma levels land within 10-15 minutes of starting the pump. Portal pressure drops measurably. GH, insulin, glucagon, and the full GI hormone panel stay suppressed for as long as the infusion runs. Common side effects during this phase include nausea, abdominal cramping, bradycardia, hyperglycemia, and mild hypotension.
0-30 minutes post-infusion: Plasma levels become undetectable within 15-20 minutes of turning off the pump. Then the rebound hits. GH, insulin, and glucagon all overshoot baseline. Blood glucose can swing in either direction. This is the highest-risk window for hypoglycemia in diabetic patients.
1-2 hours after cessation: All direct pharmacological effects are fully reversed. The GH rebound normalizes. Gastric acid secretion returns to baseline. No residual somatostatin activity remains beyond 30 minutes in most patients.
Detailed Timeline: Science vs Community
Peak plasma concentration within seconds of IV bolus. GH suppression and splanchnic blood flow reduction begins within 1 minute. Insulin and glucagon secretion acutely inhibited.
No community data available.
Plasma half-life ~1-3 min; levels halve rapidly without continuous infusion. All hormone suppression reverses within 15-20 minutes of a single bolus.
No community data available.
Steady-state plasma levels reached within 10-15 min of starting continuous infusion. Sustained reduction of portal pressure, GH, insulin, glucagon, and GI hormones for infusion duration.
No community data available.
Plasma levels undetectable within 15-20 min of cessation. Rebound hypersecretion of GH, insulin, and glucagon above baseline. Blood glucose may fluctuate dangerously: highest risk window for hypoglycemia in diabetic patients.
No community data available.
All direct pharmacological effects fully reversed. Rebound GH elevation normalizes. No residual somatostatin activity expected. Gastric acid secretion returns to baseline.
No community data available.
Pharmacokinetics
Source: Sheppard M et al. Multiple IV studies; SST-14 half-life 1-3 minutes (mean ~3 min). Patel YC. Front Neuroendocrinol. 1999;20(3):157-198. PMID: 10433861
Pharmacokinetics: Active Dose Over Time
t½ = ~1-3 minutes (IV); SST-28 ~2-3x longer than SST-14Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Somatostatin (SST-14 and SST-28) Legal?
Native somatostatin (SST-14, SST-28) has no FDA approval for any therapeutic indication in the United States. The regulatory classification is research-only. Somatostatin is not on the 503A bulks list (21 CFR 216.23) and appears in no FDA 503A or 503B nomination category (lists updated May 14, 2026 and March 21, 2025).
Stilamin (somatostatin 3 mg per vial) is a pharmaceutical product manufactured by Merck KGaA and registered in select European markets (Italy and others). It is not available through US distribution channels.
Research-grade somatostatin acetate is sold only as a lab reagent for in vitro and animal studies. These products are labeled "for research use only" and are not manufactured under cGMP for human administration.
WADA status: somatostatin is not named on the 2026 Prohibited List. Athletes should verify with their anti-doping organization.
All information on this page is for educational and research reference only. It does not constitute medical advice. Somatostatin use in any clinical setting requires direct physician supervision, hospital-grade IV delivery equipment, and continuous monitoring.
Evidence grade: Approved outside the US (Peptide Evidence Gap, October 2026)
Who Should Consider Somatostatin (SST-14 and SST-28)
- Researchers studying somatostatin receptor pharmacology and signaling
- Endocrinologists performing diagnostic provocative tests (e.g., insulinoma workup)
- Clinical investigators studying GH regulation and pituitary physiology
- Gastroenterologists managing acute variceal bleeding (historical/specialized use)
- Neuroscience researchers studying CNS somatostatin pathways
- Pharmacologists developing novel somatostatin receptor-targeted therapeutics
Related Peptides
What Changed for Somatostatin (SST-14 and SST-28)
Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations
References
- [1]Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding (Burroughs et al., Gastroenterology 1990) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the ABOVE randomised trial (Avgerinos et al., Lancet 1997) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding (Planas et al., Hepatology 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Somatostatin and somatostatin receptors: from basic concepts to clinical applications (opens in a new tab)PubMed 20541669Review
- Somatostatin, somatostatin analogues and somatostatin receptor dynamics in the biology of cancer progression (opens in a new tab)PubMed 22934849Review
- Somatostatin and the gastrointestinal tract (opens in a new tab)PubMed 19907319Review
- Molecular basis for the selective G protein signaling of somatostatin receptors (opens in a new tab)PubMed 36138141PubMed
- FDA: Bulk drug substances nominated for use in compounding under section 503A, categories (updated May 14, 2026) (opens in a new tab)Review
- FDA: Bulk drug substances nominated for use in compounding under section 503B, categories (updated March 21, 2025) (opens in a new tab)Review
- 21 CFR 216.23: Bulk drug substances that can be used to compound drug products under section 503A (eCFR) (opens in a new tab)Review
- World Anti-Doping Agency, 2026 Prohibited List: S0 non-approved substances, prohibited at all times (opens in a new tab)Review
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Somatostatin (SST-14 and SST-28)?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: None. Community mentions on Reddit: Zero self-administration threads found.
39,158 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.